This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)

Tipranks - Tipranks - Wed Jun 3, 10:04AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC).

Claim 55% Off TipRanks

Labcorp Holdings (LH)

Argus Research analyst David Toung maintained a Buy rating on Labcorp Holdings today and set a price target of $310.00. The company’s shares closed last Tuesday at $257.82, close to its 52-week high of $258.59.

According to TipRanks.com, Toung is a 4-star analyst with an average return of 8.3% and a 61.7% success rate. Toung covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Integra Lifesciences, and Edwards Lifesciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Labcorp Holdings with a $309.86 average price target, a 21.3% upside from current levels. In a report issued on May 27, TipRanks – xAI also upgraded the stock to Buy with a $286.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Moderna (MRNA)

William Blair analyst Myles Minter maintained a Hold rating on Moderna today. The company’s shares closed last Tuesday at $44.80, close to its 52-week low of $29.25.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 34.2% and a 60.1% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Moderna with a $44.35 average price target, representing a -2.2% downside. In a report released yesterday, Bernstein also maintained a Hold rating on the stock.

Celcuity (CELC)

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Celcuity, with a price target of $165.00. The company’s shares closed last Tuesday at $95.51.

According to TipRanks.com, McCammon is a 5-star analyst with an average return of 83.0% and a 57.9% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Monte Rosa Therapeutics, and Inhibrx Biosciences Inc. ;'>

Celcuity has an analyst consensus of Strong Buy, with a price target consensus of $172.38, which is an 81.5% upside from current levels. In a report issued on May 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $185.00 price target.

Read More on LH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).